Enterprise Value
706.8M
Cash
441M
Avg Qtr Burn
-79.48M
Short % of Float
18.00%
Insider Ownership
0.73%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
THIOLA® EC (tiopronin) Details Kidney disease, Cystinosis | Approved Quarterly sales | |
FILSPARI (Sparsentan) Details Kidney disease, IgA nephropathy | Approved Quarterly sales | |
FILSPARI (Sparsentan) Details Kidney disease, IgA nephropathy | PDUFA Approval decision | |
CDCA (Chenodal/ chenodeoxycholic acid) Details Cerebrotendinous xanthomatosis | Phase 3 Data readout | |
Pegtibatinase (TVT-058) Details Homocystinuria | Phase 3 Data readout | |
Sparsentan Details Kidney disease, Focal segmental glomerulosclerosis | Phase 3 Update | |
Sparsentan Details Kidney disease, Glomerular diseases | Phase 2 Update |